Hemophilia in Medical Technology
Navigation Links
Hemophilia in Medical Technology
... Factor IX (rFIX) Product for the Treatment of hemophilia B
LAGUNA NIGUEL, Calif., Feb. 12 ... of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies ... and pharmacokinetics of IB1001 in patients with hemophilia B, compared with the commercially available rFIX ...
... damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage. This ... a treatment regimen recommended by the National hemophilia Foundation's Medical and Scientific Advisory ... care of patients, especially young children, with hemophilia A," said Craig Kessler, M.D., Georgetown ...
... line of products and more than two decades of hemophilia A research, collaboration and community building at the 2008 World Federation of hemophilia (WFH) World Congress in Istanbul, Turkey. More ... of safe, effective treatment for people with hemophilia A. Since then, Bayer's Kogenate(R) line of ...
... more convenient treatment option for hemophilia patients with inhibitors ATLANTA, Dec. 10 ... may be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop ... as significantly reduce the number of injections hemophilia patients with inhibitors need during surgical ...
... of the bleeding disorder associated with hemophilia B. Upon FDA approval of the IND application, ... to facilitate prophylactic care of the hemophilia B patients worldwide. Our ultimate goal is to ... availability of lower-cost rFIX products to treat hemophilia B could facilitate more prophylactic use, as well ...
... global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential areas include multiple sclerosis (interferon-B), hemophilia (Factor VIII), pediatric growth hormone deficiency (human growth hormone) and diabetes (insulin). Founded in 2000, Medgenics is a ...
... not known at this time. Diabetes and high blood sugar have occurred in patients taking protease inhibitors, such as KALETRA. Some patients with hemophilia have increased bleeding with protease inhibitors. The effects of KALETRA on pregnant women or their unborn babies are not known. Mothers taking ...
... such as cancers, sickle cell disease and thalassemia, diabetes, asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia and cystic fibrosis. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and services that ...
... products to market. Year to date, the Company has obtained three new product approvals in the following therapeutic areas: major depressive disorder, hemophilia A and opioid-induced constipation. About Community-Acquired Pneumonia CAP is defined as pneumonia acquired outside a hospital or long-term care ...
... market. In the first quarter of 2008 alone, Wyeth obtained three new product approvals in the following therapeutic areas: major depressive disorder, hemophilia A and opioid-induced constipation. Pneumococcal Disease According to the World Health Organization (WHO), pneumococcal disease is the number one ...
... sulfate). Signs or symptoms of kidney stones include pain in the side, blood in the urine, and pain when urinating. * Some patients with hemophilia have increased bleeding problems with protease inhibitor medicines like REYATAZ. Changes in body fat have been seen in some patients taking ...
... of recombinant Factor IX to treat patients with hemophilia B. The data were highlighted in an oral ... is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor ... is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of ...
... increase in the annual bleed rate in people with hemophilia A. The findings from ADAPT suggest that ... receiving prophylaxis for the management of hemophilia A," said Peter W. Collins M.D., FRCP, FRCPath, ... relating treatment with outcomes for people with hemophilia A," said Bruce Ewenstein, M.D., Ph.D., global ...
... Interactions). As with other intramuscular injections, GARDASIL should not be given to individuals with bleeding disorders such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If ...
... spasm and spasticity and AV411 for neuropathic pain. Additionally, the company has in development AV513, a compound for the treatment of hemophilia A and B. For more information about Avigen, consult the company's website at http://www.avigen.com ....
... and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors. In 2006, GTC was granted a patent in the United States through 2021 for the production of ...
... is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo ...
... damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage. This ... a treatment regimen recommended by the National hemophilia Foundation's Medical and Scientific Advisory ... care of patients, especially young children, with hemophilia A," said Craig Kessler, M.D., Georgetown ...
... line of products and more than two decades of hemophilia A research, collaboration and community building at the 2008 World Federation of hemophilia (WFH) World Congress in Istanbul, Turkey. More ... of safe, effective treatment for people with hemophilia A. Since then, Bayer's Kogenate(R) line of ...
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
... candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using ... doses than current therapy. In established hemophilia models of acute bleeding, CB 813 has demonstrated ... for CB 813 and commence human clinical studies in hemophilia patients in 2009. "Patients receiving factor ...Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
... develop recombinant Factor IX proteins to treat hemophilia B. Baxter will develop both an unmodified ... prophylaxis of bleeding in hemophilia B patients. hemophilia B is the second most common type of hemophilia, ... and with an estimated 133,000 people living with hemophilia B worldwide. "Extending our recombinant ...... more convenient treatment option for hemophilia patients with inhibitors ATLANTA, Dec. 10 ... may be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop ... as significantly reduce the number of injections hemophilia patients with inhibitors need during surgical ...
... of the bleeding disorder associated with hemophilia B. Upon FDA approval of the IND application, ... to facilitate prophylactic care of the hemophilia B patients worldwide. Our ultimate goal is to ... availability of lower-cost rFIX products to treat hemophilia B could facilitate more prophylactic use, as well ...
... global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential areas include multiple sclerosis (interferon-B), hemophilia (Factor VIII), pediatric growth hormone deficiency (human growth hormone) and diabetes (insulin). Founded in 2000, Medgenics is a ...
KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research
... would turn off automatically in the body. In addition to helping soldiers, the Hemostat has potential for use in civilian surgery and cases of hemophilia and hemorrhagic stroke. Phillips is also working on ways to add a stem cell homing factor gene to the Hemostat system that would cause stem cells to ...... not known at this time. Diabetes and high blood sugar have occurred in patients taking protease inhibitors, such as KALETRA. Some patients with hemophilia have increased bleeding with protease inhibitors. The effects of KALETRA on pregnant women or their unborn babies are not known. Mothers taking ...
... such as cancers, sickle cell disease and thalassemia, diabetes, asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia and cystic fibrosis. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and services that ...
... products to market. Year to date, the Company has obtained three new product approvals in the following therapeutic areas: major depressive disorder, hemophilia A and opioid-induced constipation. About Community-Acquired Pneumonia CAP is defined as pneumonia acquired outside a hospital or long-term care ...
... market. In the first quarter of 2008 alone, Wyeth obtained three new product approvals in the following therapeutic areas: major depressive disorder, hemophilia A and opioid-induced constipation. Pneumococcal Disease According to the World Health Organization (WHO), pneumococcal disease is the number one ...
... sulfate). Signs or symptoms of kidney stones include pain in the side, blood in the urine, and pain when urinating. * Some patients with hemophilia have increased bleeding problems with protease inhibitor medicines like REYATAZ. Changes in body fat have been seen in some patients taking ...
... of recombinant Factor IX to treat patients with hemophilia B. The data were highlighted in an oral ... is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor ... is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of ...
... increase in the annual bleed rate in people with hemophilia A. The findings from ADAPT suggest that ... receiving prophylaxis for the management of hemophilia A," said Peter W. Collins M.D., FRCP, FRCPath, ... relating treatment with outcomes for people with hemophilia A," said Bruce Ewenstein, M.D., Ph.D., global ...
New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
... any intramuscular injection can cause injection site hematoma, Adacel vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the ...New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine
... Interactions). As with other intramuscular injections, GARDASIL should not be given to individuals with bleeding disorders such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If ...... Interactions). As with other intramuscular injections, GARDASIL should not be given to individuals with bleeding disorders such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If ...
... spasm and spasticity and AV411 for neuropathic pain. Additionally, the company has in development AV513, a compound for the treatment of hemophilia A and B. For more information about Avigen, consult the company's website at http://www.avigen.com ....
... and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors. In 2006, GTC was granted a patent in the United States through 2021 for the production of ...
... is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo ...
Other ContentssepalshomologyhomologyhomologyhomologyhomologyepitopeepitopeepitopeepitopeepitopesequentialsequentialsequentialsequentialsequentialsequentialsequentialsequentialserosataggedtaggedtaggedtaggedtaggedtaggedsequencerOther TagsLesteLesteLesteLesteGlutGlutGlutDemiDemiDemiDemiDemiOther Tagsaccumulate 2accumulate 3accumulate 4accumulate 5explains 2explains 3explains 4explains 5explains 6explains 7explains 8explains 9explains 10transporter 2deteriorate 2difference 2difference 3difference 4difference 5difference 6difference 7difference 8difference 9difference 10brand 2
(Date:12/2/2009)... Foundation is pleased to announce the 2009 winner..., A. N. Pritzker Distinguished Service Professor E...and Molecular Biology, The University of Chicago, ...memorate the 15th anniversary of the Manpei Suzuki...ghtened researchers in the field of diabetes aroun...
(Date:12/2/2009)... the first identification of substances involved i...harmless marine bacteria into killers that cause "...ironmental Science & Technology , a semi-monthly j...leaching already has destroyed up to 30 percent of...hing for ways to slow or stop the damage. One know...
(Date:12/2/2009)... SHORES, Calif. and PALM HARBOR, Fla., Dec. 2 /PRN...orporation ("CIC") (OTC Bulletin Board: CICI), a l...for business process automation in the financial i...signature verification and Docubase Systems Inc. (...cument Management (EDM) software provider announce...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 1Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 2Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 3Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 4Larta Institute Wins National Science Foundation 28NSF 29 Contract 55481 1Larta Institute Wins National Science Foundation 28NSF 29 Contract 55481 2Larta Institute Wins National Science Foundation 28NSF 29 Contract 55481 3Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 1Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 2Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 3(Date:12/2/2009)...swire-USNewswire/ -- The American Association of P...pin Regional Poison Center in Minneapolis, Minneso...r milestone for the center. The designation by th... among 58 accredited poison centers in the United ...complishment. It means we have met the national st...
(Date:12/2/2009)...swire-USNewswire/ -- In response to a press confe... ," an initiative from the U.S. Anti-Doping Agen...r Responsible Nutrition (CRN), the leading trade a...ustry, issued the following statement: ,, Sta..., "We share the concerns of Travis Tygart (USAD...
(Date:12/2/2009)...ses, study finds , , WEDNESDAY, Dec. 2 (...al rates for advanced lung cancer patients in the ...has found. , Researchers analyzed data on more ...mall cell lung cancer (NSCLC) between 1990 and 200...l Cancer Institute,s Surveillance, Epidemiology an...
(Date:12/2/2009)... unclear, researchers say , , WEDNESDAY,...that enzyme replacement therapy can make a major d...e, a rare illness that affects the kidneys, heart ...o the lack of an enzyme that helps metabolic pathw...boosts the risk for a stroke, heart attack and kid...
(Date:12/2/2009)... Researchers from aroun...ancer research at the annual American Society of H... 4-8, 2009. ,, Throughout the ASH conference, ... including Chief Medical Officer Barton Kamen, M.D...s Hildy Dillon, and Vice President, Research Commu...
Breaking Medicine News(10 mins):Health News:Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Gains Made in Lung Cancer Survival 2[1] Hennepin Regional Poison Center Designated as an Accredited Poison Control Center[1] CRN Responds to 'Supplement Safety Now' Initiative[0] Gains Made in Lung Cancer Survival[0] Enzyme Replacement May Help in Fabry Disease[1] The Leukemia & Lymphoma Society Available to Comment on Findings Presented at American Society of Hematology Conference
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |